ES2162235T3 - Piridazinaminas inhibidoras de la angiogenesis. - Google Patents

Piridazinaminas inhibidoras de la angiogenesis.

Info

Publication number
ES2162235T3
ES2162235T3 ES97901059T ES97901059T ES2162235T3 ES 2162235 T3 ES2162235 T3 ES 2162235T3 ES 97901059 T ES97901059 T ES 97901059T ES 97901059 T ES97901059 T ES 97901059T ES 2162235 T3 ES2162235 T3 ES 2162235T3
Authority
ES
Spain
Prior art keywords
6alkyl
alk
amino
6alkyloxy
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97901059T
Other languages
English (en)
Inventor
Raymond Antoine Stokbroekx
Der Aa Marcel Jozef Maria Van
Marc Willems
Lieven Meerpoel
Marcel Gerebernus Maria Luyckx
Robert W Tuman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2162235T3 publication Critical patent/ES2162235T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I), SUS FORMAS DE N - OXIDOS, SUS SALES DE ADICION FARMACEUTICAMENTE ACEPTABLES Y LAS FORMAS ESTEREOQUIMICAMENTE ISOMERICAS DE LOS MISMOS, DONDE X ES CH O N; M ES 2 O 3 Y N ES 1, 2 O 3; DONDE 1 O 2 ATOMOS DE CARBONO DE LOS GRUPOS CH 2 DE LA FRACCION (A), QUE PUEDE CONTENER TAMBIEN UN ENLACE DOBLE, PUEDEN ESTAR SUSTITUIDOS POR ALQUILO, AMINO, AMINOCARBONILO C 1-6 , MONO - O DI(ALQUIL C 1-6 )AMINO, ALQUILOXICARBONILO C 1-6 , ALQUILCARBONILAMINO C 1-6 , HIDROXILO O ALQUILOXI C 1-6 ; Y/O 2 ATOMOS DE CARBONO DE DICHOS GRUPOS CH 2 PUEDEN ESTAR PUENTEADOS CON ALCANODIILO C 2-4 ; R 1 ES HIDROGENO, ALQUILO C 1-6 , ALQUILOXI C 1-6 , ALQUILTIO C SU B,1-6 , AMINO, MONO - O DI(ALQUIL C 1-6 )AMINO, AR, ARNH -, CICLOALQUILO, HIDROXIMETILO O BENZILOXIMETILO C 3-6 ; R SUP,2 Y R 3 SON HIDROGENO O, UNIDOS, PUEDEN FORMAR UN RAD ICAL DIVALENTE DE FORMULA - CH = CH - CH = CH -; EN CASO DE QUE X REPRESENTE CH, L ES UN RADICAL L 1 , L 2 O L 3; O, EN CASO DE QUE X REPRESENTE N, EL RADICAL L ES UN RADICAL L 2 O L 3 ; L 1 ES AR - ALQUILOXI C 16 , AR - OXI, AR - TIO, AR - CARBONILAMINO, DI - AR - METILOXI , N AR - PIPERAZINILO, N - AR - HOMOPIPERAZINILO, 2 BENZILIMIDAZOLINONILO, AR - NR 4 -, AR - ALC - NR 4 -, AR - NR SUP ,4 - ALC - NR 5 -, O HET - NR 4 -; L 2 ES AR, AR - CARBONILO, AR - CH = CH - CH 2 -, NAFTALENILO O HET; L 3 ES ALQUILO C 1-6 SUSTITUIDO POR UNO O DOS RADICALES SELECCIONADOS A PARTIR DE AR, AR - OXI O AR - TIO, SUSTITUIDOS A SU VEZ OPCIONALMENTE POR CIANO O HIDROXILO; 2, 2 DIMETIL - 1, 2, 3, 4 - TETRAHIDO - NAFTALENILO; 2, 2 - DIMETIL 1H - 2, 3 - DIHIDROINDENILO; AR - PIPERIDINILO O AR - NR 4 ALC -; R 4 Y R 5 SE SELECCIONAN CADA UNO INDEPENDIENTEMENTE A PARTIR DE HIDROGENO O ALQUILO C 1-6 ; ALC ES ALCANODIILO C 1-6 . LA INVENCION DESCRIBE ASIMISMO LA PREPARACION DE DICHOS COMPUESTOS, COMPOSICIONES QUE LOS CONTIENEN Y SU UTILIZACION COMO MEDICAMENTOS.
ES97901059T 1996-01-15 1997-01-14 Piridazinaminas inhibidoras de la angiogenesis. Expired - Lifetime ES2162235T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96200085 1996-01-15

Publications (1)

Publication Number Publication Date
ES2162235T3 true ES2162235T3 (es) 2001-12-16

Family

ID=8223585

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97901059T Expired - Lifetime ES2162235T3 (es) 1996-01-15 1997-01-14 Piridazinaminas inhibidoras de la angiogenesis.

Country Status (21)

Country Link
US (1) US5985878A (es)
EP (1) EP0876366B1 (es)
JP (1) JP4169368B2 (es)
KR (1) KR100443893B1 (es)
CN (1) CN1104430C (es)
AT (1) ATE203534T1 (es)
AU (1) AU717744B2 (es)
CA (1) CA2237273C (es)
DE (1) DE69705819T2 (es)
DK (1) DK0876366T3 (es)
ES (1) ES2162235T3 (es)
GR (1) GR3036900T3 (es)
IL (1) IL124461A (es)
MY (1) MY117098A (es)
NO (1) NO309653B1 (es)
NZ (1) NZ326354A (es)
PT (1) PT876366E (es)
SI (1) SI0876366T1 (es)
TW (1) TW480256B (es)
WO (1) WO1997026258A1 (es)
ZA (1) ZA97288B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228871B1 (en) 1995-07-10 2001-05-08 Merck & Co., Inc. Angiogenesis inhibitors
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
IL164568A0 (en) 1997-05-14 2005-12-18 Atherogenics Inc Compounds and methods for the inhibition of the expression of vcam-1
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US6852878B2 (en) 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
US6265407B1 (en) 1997-06-24 2001-07-24 Janssen Pharmaceutica N.V. Angiogenesis inhibiting thiadiazolyl pyridazine derivatives
HU224812B1 (en) * 1997-06-24 2006-02-28 Janssen Pharmaceutica Nv Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives, process for producing them and pharmaceutical compositions containing the same
US6833369B2 (en) 1997-06-24 2004-12-21 Janssen Pharmaceutica, Nv Angiogenesis inhibiting 5-substituted-1,2,4,-thiadiazolyl derivatives
JP2002512630A (ja) * 1997-06-24 2002-04-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 血管形成抑制チアジアゾリルピリダジン誘導体
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
AR013693A1 (es) * 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
ATE491689T1 (de) * 1997-10-27 2011-01-15 Neurosearch As Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren
AU1600599A (en) * 1998-02-27 1999-09-15 Warner-Lambert Company Heterocyclic substituted aniline calcium channel blockers
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
US6833370B1 (en) * 1999-05-21 2004-12-21 Abbott Laboratories Heterocycle substituted aminoazacycles useful as central nervous system agents
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
NZ519981A (en) * 2000-01-20 2005-02-25 Eisai Co Ltd Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
IT1316986B1 (it) * 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
CA2404044A1 (en) 2000-04-11 2001-10-18 Atherogenics, Inc. Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
US7208503B2 (en) 2000-04-21 2007-04-24 Janssen Pharmaceutica N.V. Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0111078D0 (en) 2001-05-04 2001-06-27 Novartis Ag Organic compounds
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7754711B2 (en) * 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
EP1648874B1 (en) * 2003-07-30 2011-10-05 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
DE102004003812A1 (de) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Arylsubstituierte Heterozyklen, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
TW200533356A (en) * 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
EP1827438B2 (en) * 2004-09-20 2014-12-10 Xenon Pharmaceuticals Inc. Piperazin derivatives for inhibiting human stearoyl-coa-desaturase
EP1807085B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580762A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AR051091A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
CA2598456A1 (en) * 2005-02-16 2006-08-24 Schering Corporation Heterocyclic substituted piperazines with cxcr3 antagonist activity
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
JP2009501733A (ja) * 2005-07-20 2009-01-22 メルク フロスト カナダ リミテツド ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのヘテロ芳香族化合物
EP1966183A4 (en) * 2005-12-20 2010-12-29 Merck Frosst Canada Ltd HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A-DELTA-9-DESATURASE
TW200826936A (en) 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AR064965A1 (es) 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
WO2008118948A1 (en) 2007-03-26 2008-10-02 Atherogenics, Inc. Methods and compositions of derivatives of probucol for the treatment of diabetes
CA2703477C (en) 2007-10-25 2016-10-11 Exelixis, Inc. Pyridinyl substituted tropane compounds and uses thereof
UA102250C2 (ru) 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
EP2364185B1 (en) 2008-11-03 2013-05-22 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
MX2011005176A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
CA2743483C (en) 2008-11-17 2014-03-11 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
WO2011002067A1 (ja) * 2009-07-02 2011-01-06 武田薬品工業株式会社 複素環化合物およびその用途
WO2013085954A1 (en) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors
US9102669B2 (en) 2011-12-06 2015-08-11 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN108912116A (zh) * 2018-08-15 2018-11-30 翟学旭 一种含氮杂环类衍生物及其在视网膜疾病中的应用
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
JP2023546536A (ja) 2020-10-13 2023-11-02 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
US20250333397A1 (en) * 2021-08-30 2025-10-30 Remix Therapeutics Inc. Compounds and methods for modulating splicing
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001125A (en) * 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US4992433A (en) * 1987-11-23 1991-02-12 Janssen Pharmaceutica N.V. Novel pyridazinamine derivatives
US5461053A (en) * 1989-02-07 1995-10-24 Sanofi Pyridazine derivatives
FR2663326B2 (fr) * 1989-11-17 1992-10-16 Sanofi Sa Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant.
GB8911158D0 (en) * 1989-05-16 1989-07-05 Janssen Pharmaceutica Nv Antiviral pyridazinamines
NZ233526A (en) * 1989-05-15 1991-09-25 Janssen Pharmaceutica Nv Pyridazine derivatives and their pharmaceutical compositions
ZA9010357B (en) * 1989-12-26 1992-08-26 Janssen Pharmaceutica Nv Antipicornaviral pyridazinamines
JO1645B1 (en) * 1989-12-26 1991-11-27 شركة جانسين فارماسوتيكا ان. في Pyridazine compounds are antibacterial viruses
US5100893A (en) * 1990-04-18 1992-03-31 Janssen Pharmaceutica N.V. Antipicornaviral pyridazinamines
US5242924A (en) * 1992-07-02 1993-09-07 Sterling Winthrop Inc. Tetrazolyl-(phenoxy and phenoxyalkyl)-piperidinylpyridazines as antiviral agents

Also Published As

Publication number Publication date
GR3036900T3 (en) 2002-01-31
JP4169368B2 (ja) 2008-10-22
NO982037D0 (no) 1998-05-05
ATE203534T1 (de) 2001-08-15
US5985878A (en) 1999-11-16
JP2000503014A (ja) 2000-03-14
NZ326354A (en) 1999-05-28
DE69705819T2 (de) 2002-04-11
PT876366E (pt) 2002-01-30
CN1104430C (zh) 2003-04-02
IL124461A (en) 2000-07-26
AU1443997A (en) 1997-08-11
NO982037L (no) 1998-09-15
DE69705819D1 (de) 2001-08-30
NO309653B1 (no) 2001-03-05
DK0876366T3 (da) 2001-11-05
MY117098A (en) 2004-05-31
CA2237273A1 (en) 1997-07-24
TW480256B (en) 2002-03-21
KR100443893B1 (ko) 2004-10-15
CN1208415A (zh) 1999-02-17
EP0876366B1 (en) 2001-07-25
EP0876366A2 (en) 1998-11-11
AU717744B2 (en) 2000-03-30
SI0876366T1 (en) 2001-12-31
WO1997026258A1 (en) 1997-07-24
IL124461A0 (en) 1998-12-06
CA2237273C (en) 2009-01-13
ZA97288B (en) 1998-07-14
KR19990067654A (ko) 1999-08-25

Similar Documents

Publication Publication Date Title
ES2162235T3 (es) Piridazinaminas inhibidoras de la angiogenesis.
NO20021399L (no) Kazolinderivater og deres anvendelse som farmasöyter
MX9803407A (es) Derivados de piperazina 1-(1,2-disustituido piperidinil)-4-sustituidos.
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
WO1993001165A3 (en) Aromatic compounds, compositions containing them and their use in therapy
EA199800604A1 (ru) Производные 1-(1,2-дизамещенный пиперидинил)-4-замещенного пиперидинина как антагонисты рецепторов тахикинина
AR018175A1 (es) Compuestos de indol-3-glioxilamidas sustituidas, utiles como medicamentos antitumorales, composiciones farmaceuticas formuladas con dichos derivados,utilizacion de dichos derivados para la preparacion de medicamentos antitumorales y los medicamentos asi preparados.
JO1645B1 (en) Pyridazine compounds are antibacterial viruses
BRPI0417007A (pt) agentes antivirais de diazaindol-dicarbonil-piperazinila
CA1249830A (en) ANTIHISTAMINES WITH DIPHENYL AND PHENYLPYRIDYL GROUPS
MY121580A (en) 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl-and imidazopyridinyl)- piperidine derivatives
AR043271A1 (es) Compuestos de dihidropironas con heterociclos unidos y su uso en composicines farmaceuticas que poseen actividad inhibidora de hiv proteasa
DE69838385D1 (de) Angiogenese-hemmende 5-substituierte-1,2,4-thiadiazolylderivate
MY120046A (en) Angiogenesis inhibiting thiadiazolyl pyridazine derivatives.
PT1068200E (pt) Antifungicos 1,3-dioxolano 2,4,4-tir-substituidos
WO2002024711A1 (en) Novel thiazole bicyclic compounds
FI101071B (fi) Menetelmä terapeuttisesti käyttökelpoisten 3,4-dihydroisokinoliini-N-o ksidien valmistamiseksi
SE9902147L (sv) Nya föreningar och farmaceutiska kompositioner innehållande desamma
AR030927A1 (es) Compuestos de azol, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica y proceso para la preparacion del mismo

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 876366

Country of ref document: ES